2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Nichols Weston | 10% Owner | 8,963,500 | Oct 30, 2025 |
| Lynx1 Capital Management LP | 10% Owner | 8,963,500 | Oct 30, 2025 |
| MPM Oncology Impact Management GP LLC | 10% Owner | 7,805,483 | Aug 25, 2021 |
| Gadicke Ansbert | Director | 7,648,268 | Feb 10, 2023 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | Feb 26, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 48.1 | -1,780 | -1.01% | ✓ | $25.2K |
| Feb 23, 2026 | Feb 25, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 42.5 | -5,353 | -2.94% | ✓ | $76.6K |
| Feb 24, 2026 | Feb 25, 2026 | AHMED NADIM | CEO | Sell | 22.5 | -13,515 | -3.34% | ✗ | $195.6K |
| Feb 24, 2026 | Feb 25, 2026 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 22.5 | -4,582 | -2.78% | ✗ | $66.3K |
| Feb 24, 2026 | Feb 25, 2026 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 22.5 | -3,601 | -2.73% | ✗ | $52.1K |
| Feb 20, 2026 | Feb 23, 2026 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 22.5 | -4,982 | -2.94% | ✗ | $67.9K |
| Feb 20, 2026 | Feb 23, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 38.8 | -11,742 | -3.13% | ✓ | $165.4K |
| Feb 20, 2026 | Feb 23, 2026 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 22.5 | -3,742 | -2.76% | ✗ | $51K |
| Feb 20, 2026 | Feb 23, 2026 | AHMED NADIM | CEO | Sell | 22.5 | -16,381 | -3.89% | ✗ | $223.1K |
| Feb 20, 2026 | Feb 23, 2026 | Fenton Mary Kay | CFO | Sell | 22.5 | -4,398 | -3.36% | ✗ | $59.9K |
| Feb 18, 2026 | Feb 19, 2026 | SUMER JACQUELYN L | Chief Legal Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2026 | Feb 19, 2026 | Jones Jeffrey Alan | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2026 | Feb 19, 2026 | AHMED NADIM | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2026 | Feb 19, 2026 | Savill Corrine | Chief Business Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2026 | Feb 19, 2026 | Fenton Mary Kay | CFO | Neutral | 90.0 | +68,750 | 110.84% | ✗ | - |
| Feb 18, 2026 | Feb 19, 2026 | Michaelson Jennifer | Chief Scientific Officer | Neutral | 90.0 | +57,500 | 44.85% | ✗ | - |
| Feb 12, 2026 | Feb 13, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 45.0 | -416 | -0.32% | ✗ | $5K |
| Jan 22, 2026 | Jan 23, 2026 | Michaelson Jennifer | Chief Scientific Officer | Sell | 40.6 | -4,000 | -3.02% | ✓ | $49.2K |
| Dec 31, 2025 | Jan 5, 2026 | Fenton Mary Kay | CFO | Neutral | 47.5 | +27 | 0.04% | ✗ | - |
| Dec 23, 2025 | Dec 29, 2025 | AHMED NADIM | CEO | Sell | 22.5 | -9,922 | -2.30% | ✗ | $99.3K |
| Dec 19, 2025 | Dec 22, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 48.1 | -1,345 | -1.00% | ✓ | $13.5K |
| Dec 18, 2025 | Dec 19, 2025 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 26.3 | -3,480 | -2.51% | ✗ | $33.7K |
| Dec 18, 2025 | Dec 19, 2025 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 26.3 | -4,632 | -2.66% | ✗ | $44.8K |
| Dec 18, 2025 | Dec 19, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 26.3 | -2,898 | -2.12% | ✗ | $28K |
| Dec 12, 2025 | Dec 16, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 45.0 | -3,143 | -2.24% | ✓ | $38.4K |
| Nov 24, 2025 | Nov 25, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 45.0 | -4,000 | -2.82% | ✓ | $49.2K |
| Oct 28, 2025 | Oct 30, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 87.5 | +165,667 | 1.88% | ✗ | $1.4M |
| Oct 14, 2025 | Oct 21, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 87.5 | +248,749 | 1.45% | ✗ | $2.1M |
| Oct 8, 2025 | Oct 10, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 96.3 | +1,459,641 | 9.91% | ✗ | $9.8M |
| Oct 10, 2025 | Lynx1 Capital Management LP | 10% Owner | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 7, 2025 | Aug 8, 2025 | Doyle Mittie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 7, 2025 | Aug 8, 2025 | Allen Andrew R | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 8, 2025 | Allen Andrew R | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 8, 2025 | Doyle Mittie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jun 12, 2025 | Jun 16, 2025 | Ryan David P. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 16, 2025 | Rosenberg Anthony | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 16, 2025 | Webster Stephen W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 16, 2025 | Meek David D. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 12, 2025 | Jun 16, 2025 | Martin Anne-Marie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 25, 2025 | Feb 27, 2025 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 26.3 | -4,895 | -2.73% | ✗ | $41.8K |
| Feb 25, 2025 | Feb 27, 2025 | AHMED NADIM | CEO | Sell | 22.5 | -12,529 | -2.83% | ✗ | $106.9K |
| Feb 25, 2025 | Feb 27, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 26.3 | -3,756 | -2.58% | ✗ | $32K |
| Feb 25, 2025 | Feb 27, 2025 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 26.3 | -3,756 | -2.67% | ✗ | $32K |
| Feb 19, 2025 | Feb 21, 2025 | Michaelson Jennifer | Chief Scientific Officer | Neutral | 90.0 | +50,000 | 52.21% | ✗ | - |
| Feb 19, 2025 | Feb 21, 2025 | Savill Corrine | Chief Business Officer | Neutral | 90.0 | +37,500 | 18.43% | ✗ | - |
| Feb 19, 2025 | Feb 21, 2025 | SUMER JACQUELYN L | Chief Legal Officer | Neutral | 90.0 | +50,000 | 55.16% | ✗ | - |
| Feb 19, 2025 | Feb 21, 2025 | AHMED NADIM | CEO | Neutral | 90.0 | +180,000 | 68.40% | ✗ | - |
| Feb 19, 2025 | Feb 21, 2025 | Jones Jeffrey Alan | Chief Medical Officer | Neutral | 90.0 | +65,000 | 56.99% | ✗ | - |
| Feb 19, 2025 | Feb 21, 2025 | Fenton Mary Kay | CFO | Neutral | 90.0 | +60,000 | 100.00% | ✗ | - |
| Jan 6, 2025 | Jan 7, 2025 | Michaelson Jennifer | Chief Scientific Officer | Sell | 37.5 | -4,000 | -4.01% | ✓ | $50K |
| Dec 24, 2024 | Dec 27, 2024 | AHMED NADIM | CEO | Sell | 22.5 | -8,400 | -3.09% | ✗ | $99.7K |
| Dec 18, 2024 | Dec 20, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 22.5 | -4,693 | -4.49% | ✗ | $53.5K |
| Dec 18, 2024 | Dec 20, 2024 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 22.5 | -4,632 | -3.90% | ✗ | $52.9K |
| Dec 18, 2024 | Dec 20, 2024 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 26.3 | -3,482 | -3.70% | ✗ | $39.7K |
| Dec 12, 2024 | Dec 16, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 26.3 | -3,489 | -3.23% | ✗ | $43.7K |
| Nov 5, 2024 | Nov 7, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 32.5 | -8,000 | -6.90% | ✓ | $125.1K |
| Sep 5, 2024 | Sep 9, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 32.5 | -8,000 | -6.45% | ✓ | $144.7K |
| Aug 9, 2024 | Thistle Mary | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 8, 2024 | Aug 9, 2024 | Thistle Mary | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 5, 2024 | Jul 9, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 32.5 | -8,000 | -6.06% | ✓ | $130.6K |
| Jul 1, 2024 | Jul 2, 2024 | Michaelson Jennifer | Chief Scientific Officer | Neutral | 77.5 | +2,360 | 1.82% | ✗ | - |
| Jun 26, 2024 | Jun 27, 2024 | Webster Stephen W | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 26, 2024 | Jun 27, 2024 | Rosenberg Anthony | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 26, 2024 | Jun 27, 2024 | Martin Anne-Marie | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 26, 2024 | Jun 27, 2024 | Ryan David P. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 10, 2024 | Jun 11, 2024 | Ebeling Thomas | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 23, 2024 | May 23, 2024 | Ebeling Thomas | Director | Neutral | 90.0 | +100,699 | 149.17% | ✗ | - |
| May 15, 2024 | May 16, 2024 | Meek David D. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 16, 2024 | Meek David D. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| May 6, 2024 | May 8, 2024 | Michaelson Jennifer | Chief Scientific Officer | Sell | 20.0 | -63,606 | -13.46% | ✓ | $1.8M |
| Apr 29, 2024 | Apr 30, 2024 | Fenton Mary Kay | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 30, 2024 | Fenton Mary Kay | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 2, 2024 | Nguyen Nate | Interim PAO and PFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 22, 2024 | Feb 23, 2024 | Savill Corrine | Chief Business Officer | Neutral | 90.0 | +37,500 | 22.59% | ✗ | - |
| Feb 22, 2024 | Feb 23, 2024 | AHMED NADIM | CEO | Neutral | 90.0 | +160,000 | 143.43% | ✗ | - |
| Feb 22, 2024 | Feb 23, 2024 | Trigilio Jeffrey | CFO | Neutral | 90.0 | +50,000 | 59.58% | ✗ | - |
| Feb 22, 2024 | Feb 23, 2024 | Jones Jeffrey Alan | Chief Medical Officer | Neutral | 90.0 | +62,500 | 111.23% | ✗ | - |
| Feb 22, 2024 | Feb 23, 2024 | Michaelson Jennifer | Chief Scientific Officer | Neutral | 90.0 | +50,000 | 57.09% | ✗ | - |
| Feb 22, 2024 | Feb 23, 2024 | SUMER JACQUELYN L | Chief Legal Officer | Neutral | 90.0 | +50,000 | 113.29% | ✗ | - |
| Feb 1, 2024 | Feb 2, 2024 | Savill Corrine | Chief Business Officer | Sell | 17.5 | -40,000 | -19.42% | ✓ | $647.2K |
| Jan 29, 2024 | Jan 30, 2024 | Savill Corrine | Chief Business Officer | Sell | 17.5 | -40,000 | -19.42% | ✓ | $563.6K |
| Jan 22, 2024 | Jan 24, 2024 | Savill Corrine | Chief Business Officer | Sell | 30.0 | -40,000 | -7.38% | ✓ | $492.5K |
| Dec 26, 2023 | Dec 27, 2023 | AHMED NADIM | CEO | Sell | 26.3 | -4,272 | -3.69% | ✗ | $39.5K |
| Dec 21, 2023 | Dec 22, 2023 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 26.3 | -1,860 | -3.20% | ✗ | $15.8K |
| Dec 21, 2023 | Dec 22, 2023 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 26.3 | -1,400 | -3.07% | ✗ | $11.9K |
| Dec 21, 2023 | Dec 22, 2023 | Trigilio Jeffrey | CFO | Sell | 26.3 | -1,920 | -2.24% | ✗ | $16.3K |
| Dec 21, 2023 | Dec 22, 2023 | Michaelson Jennifer | Chief Scientific Officer | Sell | 27.5 | -1,145 | -1.29% | ✗ | $9.7K |
| Dec 18, 2023 | Dec 20, 2023 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 37.5 | -386 | -0.66% | ✗ | $3.2K |
| Dec 18, 2023 | Dec 20, 2023 | Michaelson Jennifer | Chief Scientific Officer | Sell | 45.0 | -238 | -0.27% | ✗ | $2K |
| Dec 18, 2023 | Dec 20, 2023 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 37.5 | -290 | -0.63% | ✗ | $2.4K |
| Dec 18, 2023 | Dec 20, 2023 | Trigilio Jeffrey | CFO | Sell | 45.0 | -398 | -0.46% | ✗ | $3.3K |
| Dec 12, 2023 | Dec 13, 2023 | Trigilio Jeffrey | CFO | Sell | 26.3 | -1,926 | -2.18% | ✗ | $15K |
| Dec 12, 2023 | Dec 13, 2023 | Michaelson Jennifer | Chief Scientific Officer | Sell | 27.5 | -1,068 | -1.19% | ✗ | $8.3K |
| Jun 30, 2023 | Jul 5, 2023 | Trigilio Jeffrey | CFO | Neutral | 82.5 | +2,340 | 2.73% | ✗ | - |
| Jun 28, 2023 | Jun 29, 2023 | AHMED NADIM | CEO | Sell | 37.5 | -759 | -0.65% | ✗ | $8.7K |
| Jun 20, 2023 | Jun 21, 2023 | Jones Jeffrey Alan | Chief Medical Officer | Sell | 37.5 | -387 | -0.66% | ✗ | $5K |
| Jun 20, 2023 | Jun 21, 2023 | Michaelson Jennifer | Chief Development Officer | Sell | 45.0 | -238 | -0.26% | ✗ | $3.1K |
| Jun 20, 2023 | Jun 21, 2023 | Trigilio Jeffrey | CFO | Sell | 45.0 | -399 | -0.46% | ✗ | $5.2K |
| Jun 20, 2023 | Jun 21, 2023 | SUMER JACQUELYN L | Chief Legal Officer | Sell | 37.5 | -291 | -0.63% | ✗ | $3.8K |
| Jun 12, 2023 | Jun 14, 2023 | Trigilio Jeffrey | CFO | Sell | 45.0 | -319 | -0.37% | ✗ | $4.2K |